Nutlin-3a Induces Cytoskeletal Rearrangement and Inhibits the Migration and Invasion Capacity of P53 Wild-type Cancer Cells

Overview

Journal Mol Cancer Ther

Date 2010 Apr 8

PMID 20371712

Citations 19

Authors

Diarmuid M Moran

Carl G Maki

Affiliations

Soon will be listed here.

Abstract

MDM2 is an E3 ubiquitin ligase that binds and ubiquitinates the tumor suppressor protein p53, leading to its proteasomal degradation. Nutlin-3a (Nutlin) is a preclinical drug that binds MDM2 and prevents the interaction between MDM2 and p53, leading to p53 stabilization and activation of p53 signaling events. Previous studies have reported that Nutlin promotes growth arrest and/or apoptosis in cancer cells that express wild-type p53. In the current study, Nutlin treatment caused a cytoskeletal rearrangement in p53 wild-type human cancer cells from multiple etiologies. Specifically, Nutlin decreased actin stress fibers and reduced the size and number of focal adhesions in treated cells. This process was dependent on p53 expression but was independent of p21 expression and growth arrest. Consistent with this, Nutlin-treated cells failed to form filamentous actin-based motility structures (lamellipodia) and displayed significantly decreased directional persistence in response to migratory cues. Finally, chemotactic assays showed a p53-dependent/p21-independent decrease in migratory and invasive capacity of Nutlin-treated cells. Taken together, these findings reveal that Nutlin treatment can inhibit the migration and invasion capacity of p53 wild-type cells, adding to the potential therapeutic benefit of Nutlin and other small molecule MDM2 inhibitors. Mol Cancer Ther; 9(4); 895-905. (c)2010 AACR.

Citing Articles

Unlocking the Gateway: The Spatio-Temporal Dynamics of the p53 Family Driven by the Nuclear Pores and Its Implication for the Therapeutic Approach in Cancer.

Ikliptikawati D, Makiyama K, Hazawa M, Wong R Int J Mol Sci. 2024; 25(13).

PMID: 39000572 PMC: 11242911. DOI: 10.3390/ijms25137465.

Impacts of Nutlin-3a and exercise on murine double minute 2-enriched glioma treatment.

Chen Y, Fan Z, Luo Z, Kang X, Wan R, Li F Neural Regen Res. 2024; 20(4):1135-1152.

PMID: 38989952 PMC: 11438351. DOI: 10.4103/NRR.NRR-D-23-00875.

Stimuli-sensitive Chitosan-based Nanosystems-immobilized Nucleic Acids for Gene Therapy in Breast Cancer and Hepatocellular Carcinoma.

Naghib S, Ahmadi B, Mozafari M Curr Top Med Chem. 2024; 24(17):1464-1489.

PMID: 38752630 DOI: 10.2174/0115680266293173240506054439.

Current insights into the regulation of programmed cell death by TP53 mutation in cancer.

Su Y, Sai Y, Zhou L, Liu Z, Du P, Wu J Front Oncol. 2022; 12:1023427.

PMID: 36313700 PMC: 9608511. DOI: 10.3389/fonc.2022.1023427.

Targeting mutant p53 for cancer therapy: direct and indirect strategies.

Hu J, Cao J, Topatana W, Juengpanich S, Li S, Zhang B J Hematol Oncol. 2021; 14(1):157.

PMID: 34583722 PMC: 8480024. DOI: 10.1186/s13045-021-01169-0.

References

Kedrin D, van Rheenen J, Hernandez L, Condeelis J, Segall J . Cell motility and cytoskeletal regulation in invasion and metastasis. J Mammary Gland Biol Neoplasia. 2007; 12(2-3):143-52. DOI: 10.1007/s10911-007-9046-4. View

Alexandrova A, Ivanov A, Chumakov P, Kopnin B, Vasiliev J . Changes in p53 expression in mouse fibroblasts can modify motility and extracellular matrix organization. Oncogene. 2000; 19(50):5826-30. DOI: 10.1038/sj.onc.1203944. View

Murakami T, Maki W, Cardones A, Fang H, Kyi A, Nestle F . Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res. 2002; 62(24):7328-34. View

Friedl P, Wolf K . Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003; 3(5):362-74. DOI: 10.1038/nrc1075. View

Qian L, Mizumoto K, Maehara N, Ohuchida K, Inadome N, Saimura M . Co-cultivation of pancreatic cancer cells with orthotopic tumor-derived fibroblasts: fibroblasts stimulate tumor cell invasion via HGF secretion whereas cancer cells exert a minor regulative effect on fibroblasts HGF production. Cancer Lett. 2003; 190(1):105-12. DOI: 10.1016/s0304-3835(02)00517-7. View

Guo F, Zheng Y . Rho family GTPases cooperate with p53 deletion to promote primary mouse embryonic fibroblast cell invasion. Oncogene. 2004; 23(33):5577-85. DOI: 10.1038/sj.onc.1207752. View

Momand J, Jung D, Wilczynski S, Niland J . The MDM2 gene amplification database. Nucleic Acids Res. 1998; 26(15):3453-9. PMC: 147746. DOI: 10.1093/nar/26.15.3453. View

Moskovits N, Kalinkovich A, Bar J, Lapidot T, Oren M . p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res. 2006; 66(22):10671-6. DOI: 10.1158/0008-5472.CAN-06-2323. View

Raftopoulou M, Hall A . Cell migration: Rho GTPases lead the way. Dev Biol. 2003; 265(1):23-32. DOI: 10.1016/j.ydbio.2003.06.003. View

10.

Sahai E . Mechanisms of cancer cell invasion. Curr Opin Genet Dev. 2005; 15(1):87-96. DOI: 10.1016/j.gde.2004.12.002. View

11.

Van Maerken T, Speleman F, Vermeulen J, Lambertz I, De Clercq S, Smet E . Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res. 2006; 66(19):9646-55. DOI: 10.1158/0008-5472.CAN-06-0792. View

12.

Kuo J, Wang W, Yao C, Wu P, Chen R . The tumor suppressor DAPK inhibits cell motility by blocking the integrin-mediated polarity pathway. J Cell Biol. 2006; 172(4):619-31. PMC: 2063680. DOI: 10.1083/jcb.200505138. View

13.

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

14.

Iwakuma T, Lozano G . MDM2, an introduction. Mol Cancer Res. 2004; 1(14):993-1000. View

15.

Levav-Cohen Y, Haupt S, Haupt Y . Mdm2 in growth signaling and cancer. Growth Factors. 2005; 23(3):183-92. DOI: 10.1080/08977190500196218. View

16.

Gadea G, Lapasset L, Gauthier-Rouviere C, Roux P . Regulation of Cdc42-mediated morphological effects: a novel function for p53. EMBO J. 2002; 21(10):2373-82. PMC: 126005. DOI: 10.1093/emboj/21.10.2373. View

17.

Vassilev L, Vu B, Graves B, Carvajal D, Podlaski F, Filipovic Z . In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303(5659):844-8. DOI: 10.1126/science.1092472. View

18.

Secchiero P, Corallini F, Gonelli A, Delleva R, Vitale M, Capitani S . Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res. 2006; 100(1):61-9. DOI: 10.1161/01.RES.0000253975.76198.ff. View

19.

Dow L, Kauffman J, Caddy J, Zarbalis K, Peterson A, Jane S . The tumour-suppressor Scribble dictates cell polarity during directed epithelial migration: regulation of Rho GTPase recruitment to the leading edge. Oncogene. 2006; 26(16):2272-82. DOI: 10.1038/sj.onc.1210016. View

20.

Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I . Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci. 2007; 98(11):1652-8. PMC: 11159633. DOI: 10.1111/j.1349-7006.2007.00606.x. View